Guardant Health, Inc.

Healthcare

$91.89+2.65%vs prev close

$36.36

$120.74

52W Range

+2.23 (+2.49%)Past 1M

Price

Stock Timeline

Institutional Holders

2 Holding · 0 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Cathie WoodARK Invest

LIVE

474,436

Portfolio Weight

0.34%

in ETF 3.58%

Est. Value

$43M

30D Net

Ray DalioBridgewater Associates

Increased

28,291

Portfolio Weight

0.01%

Est. Value

$3M

vs Prev Quarter

+606% (4K→28K)

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Strong Buy

Buy

Hold

Analyst Targets

avg.

$128.33

vs Current ▲ +39.7% upside

Current$91.89

Low ~ High$90.00 ~ $180.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

Barclays

Overweight

$115.00

+25.15%

$86.40

Maintain

2026-04-14

Evercore ISI Group

In-Line

$90.00

-2.06%

$89.66

Maintain

2026-04-06

Piper Sandler

Overweight

$130.00

+41.47%

$95.40

Maintain

2026-02-24

Leerink Partners

Outperform

$180.00

+95.89%

$103.10

Maintain

2026-02-20

Citigroup

Buy

$150.00

+63.24%

$103.10

Maintain

2026-02-20

1 / 34

Avg Target

$128.33

vs Current ▲ +39.7% upside

Strong Buy

22 analysts

Strong Buy 4Buy 16Hold 2

Low $90.00

Current $91.89

High $180.00

Firm	Position	Target	Upside	Close	Action	Date
Barclays	Overweight	$115.00	+25.15%	$86.40	Maintain	26.04.14
Evercore ISI Group	In-Line	$90.00	-2.06%	$89.66	Maintain	26.04.06
Piper Sandler	Overweight	$130.00	+41.47%	$95.40	Maintain	26.02.24
Leerink Partners	Outperform	$180.00	+95.89%	$103.10	Maintain	26.02.20
Citigroup	Buy	$150.00	+63.24%	$103.10	Maintain	26.02.20

1 / 34

Price Information

Previous Close$89.52

Open$89.83

Day Range$88.20 - $92.81

52-Week Range$36.36 - $120.74

1-Year Change125.26%

Trading Volume

Volume1,099,055

Avg Volume (3mo)1,974,931

Valuation

Market Cap12.2B

Book Value$-0.76

Shares Outstanding132,573,424

Financials

Revenue (TTM)982.0M

Net Income-416,276,992

EPS$-3.32

EBITDA-396,561,984

Profitability

P/E Ratio-

P/B Ratio-120.97

Return on Equity (ROE)-

Return on Assets (ROA)-15.58%

Profit Margin-42.39%

EV/EBITDA-30.89

Beta1.49

Dividend

Dividend Rate-

Dividend Yield-

Technical

RSI(14)61.31

Company Overview

Guardant Health is a precision oncology company that offers a suite of blood and tissue tests, including Guardant360 and Guardant360 CDx, to identify genetic alterations in cancer. These tests, along with data sets and software solutions like GuardantConnect, help clinicians and biopharmaceutical companies advance cancer research and therapy development. The company is a leader in liquid biopsy and comprehensive genomic profiling for cancer patients.

P/B

-120.97

Negative equity

ROE

Return on Equity

Beta

1.49

Market Volatility

RSI(14)

61.3

Neutral zone

AI-generated summary. Not investment advice.